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Background: Stromal cell-derived factor 1 (SDF-1) is a chemokine that is expressed in some cancer cells and is
involved in tumor cell migration and metastasis. CXCR7, a novel receptor for SDF-1, has been identified recently.
Research has demonstrated that SDF-1/CXCR7 interaction could play an important role in cancer progression. In this
study, we aimed to investigate the expression of the SDF-1/CXCR7 ligand receptor system and the relationship
between this expressions and clinicopathological characteristics in pancreatic adenocarcinoma.
Methods: Expressions of SDF-1 and CXCR7 in 64 cases of pancreatic adenocarcinoma tissue and 24 cases of normal
pancreatic tissue were detected immunohistochemically.
Results: Expressions of SDF-1 and CXCR7 were negative in normal pancreatic tissues. Respectively, positive
expression rates of SDF-1 and CXCR7 in pancreatic adenocarcinoma were 45.3% and 51.6%. The expression of
SDF-1 correlated with histological grades; the expression rate in moderate to low differentiation was higher than in
high differentiation (P <0.05). The expression of CXCR7 positively correlated with lymph node metastasis (P <0.05).
A log-rank test showed that the expression of SDF-1+/CXCR7+ correlated with poor prognosis (P <0.05).
Conclusions: The SDF-1/CXCR7 receptor ligand system may take part in invasive progression and metastasis of
pancreatic adenocarcinoma, and might be useful as an index for evaluating invasiveness and prognosis.
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Pancreatic adenocarcinoma is highly aggressive and has
a poor prognosis. Despite the high mortality associated
with this disease, the biology involved in the development
of pancreatic adenocarcinoma remains poorly understood.
Invasion and metastasis are important factors that affect
the prognosis of this cancer. Stromal cell-derived factor 1
(SDF-1) is a chemotactic factor for T cells, monocytes,
hematopoietic progenitor cells, dendritic cells, endothelial
cells, and tumor cells [1-4], and plays a role in a number
of important physiological processes including leukocyte
trafficking and vasculogenesis [5,6]. More importantly,
SDF-1 plays a crucial role in the process of invasion and
metastasis of tumor cells [7]; it stimulates proliferation,
dissociation, migration, and invasion in a wide variety of* Correspondence: liuz@sj-hospital.org
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unless otherwise stated.tumor cells, including breast cancer cells, pancreatic
cancer cells, and hepatocellular carcinoma cells [8,9].
Recently, a novel receptor for SDF-1, called CXCR7, has
been identified and it has been hypothesized as a new
molecular link in the chain of connections between in-
flammation and cancer [10]. CXCR7 mediates a broad
range of cellular activities, including proliferation, survival,
and adhesion by binding with SDF-1 [10]. In recent years,
upregulation of CXCR7 has been reported to promote
lung and breast tumor growth [7] and to increase prostate
cancer metastasis [11]. These results provide a reasonable
basis for a proposal that the SDF-1/CXCR7 interaction
could play an important role in cancer progression.
In this study, we explored the expression of SDF-1/
CXCR7 receptor ligand system and the relationship
between this expression and clinicopathologic charac-
teristics in pancreatic adenocarcinoma.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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A total of 64 patients who had undergone pancreatoduo-
denectomy and were diagnosed with pancreatic ductal
adenocarcinoma by histologic examination were inclu-
ded in this study. Pancreatic adenocarcinoma samples
were obtained from the Shengjing Hospital of China
Medical University from 2010 to 2012. In all, 24 samples
of normal pancreatic tissue acquired surgically from
patients who received an operation due to trauma or
benign pancreatic tumor were used in this study. All par-
ticipating patients signed the informed consent. The study
protocol conformed to the Declaration of Helsinki and
was approved by the Ethics Committee in the Shengjing
Hospital of China Medical University.Immunohistochemistry
Paraffin-embedded tissues were sectioned at 4 μm
thickness. Antigen retrieval was performed at 95°C for
20 minutes in a sodium citrate buffer solution. Endogen-
ous peroxidase activity was inhibited by incubation with
3% hydrogen peroxide for 10 min at room temperature.
The sections were incubated in 5% goat serum for 15 min,
to block any nonspecific reaction. The sections were incu-
bated with mouse anti-human SDF-1 (R&D company,
1:100 dilution) or CXCR7 (R&D company, 1:100 dilution)
at 4°C overnight. After incubation, the sections were
washed in PBS for 10 min, and were incubated with goat
anti-mouse IgG biotinylated second antibody (MAIXIN_
BIO, China) for 1 h at room temperature and thereafter
incubated in streptavidin-peroxidase complex for 30 min.
Diaminobenzidine chromogen was then added to the sec-
tions. Expressions of SDF-1 and CXCR7 were quantified
using a visual grading system based on the extent of stain-
ing (percentage of positive tumor cells graded on a scale
from 0 to 3: 0, <5%; 1, 5 to 25%; 2, 26 to 50%; 3, >50%) and
the intensity of staining (graded on a scale of 0 to 3: 0,
none; 1, weak staining; 2, moderate staining; 3, strong stain-
ing). The combined extent (E) and intensity (I) of staining
was obtained by calculating the product of E and I
(EI), which varied from 0 to 6 for each spot. Negative ex-
pression was indicated for an EI score of 0 or 1 and posi-
tive expression for EI >2.Statistical analysis
Fisher’s exact tests were used to analyze the relationship
between the expression of SDF-1 and CXCR7 and clini-
copathological characteristics. Survival curves were con-
structed using the Kaplan-Meier method and the log-rank
test was used to evaluate the statistical significance of
differences. All data were analyzed using SPSS 13.0
software (SPSS Inc., Chicago, IL); P <0.05 was considered
significant.Results
Patients’ characteristics
Of the 64 pancreatic adenocarcinoma patients, the median
age was 58 years (range 41 to 80 years), including 44 men
and 20 women. No patients received preoperative chemo-
therapy or radiotherapy. All cases were accompanied by
detailed clinical and surgical records. High differentiation
was noted in 14 patients, and moderate to low differenti-
ation in 50. The tumor-node-metastasis (TNM) stage was
I or II in 57 cases and III or IV in 7 cases. Lymph node
metastasis was observed in 37 patients. The patients’ back-
ground factors are summarized in Table 1. The follow-up
time was 3 to 26 months.
Expression levels of SDF-1 and CXCR7 protein in
pancreatic adenocarcinoma and normal pancreatic tissues
In normal pancreatic tissue, SDF-1 and CXCR7 are both
negative (Figure 1). In cancer tissues, SDF-1 and CXCR7
is highly expressed in ductal cells, but not in acinar and
stromal tissue (Figure 2). In pancreatic adenocarcinoma,
the positive expression rates of SDF-1 and CXCR7 were
45.3% (29/64) and 51.6% (33/64), respectively. The expres-
sion rates of SDF-1 and CXCR7 in cancer tissues were sig-
nificantly higher than normal tissues (P <0.05).
Correlation between SDF-1 and CXCR7 expressions and
clinicopathological characteristics in pancreatic
adenocarcinoma
We analyzed the relationship between the expressions of
SDF-1 and CXCR7 and clinicopathological characteris-
tics in pancreatic adenocarcinoma. The results showed
that SDF-1 expression was not related with age, sex, size
of tumor, TNM stage, lymph node metastasis, or distant
metastasis (Table 1). The expression of SDF-1 correlated
with histological grade of pancreatic adenocarcinoma; the
expression rate of the moderate to low differentiated group
was higher than that of the highly differentiated group
(P <0.05). Expression of CXCR7 was related with lymph
node metastasis, and the expression rate of CXCR7 in
the group with lymph node metastasis was higher than that
of the group without lymph node metastasis (P <0.05).
There was no relationship between CXCR7 expression
and age, sex, size of tumor, histological grade, TNM stage,
or distant metastasis (Table 1).
Relationship between the expressions of SDF-1 and
CXCR7 and survival time
Single analysis shows that there is no relation between the
expression of SDF-1 and CXCR7 and prognosis. Combin-
ing analysis of the relationship between the expressions of
SDF-1 and CXCR7 and prognosis reveals that the median
survival time of the SDF-1+CXCR7+ group was 6 months,
of the SDF-1+CXCR7−/SDF-1−CXCR7+ group was 9 months,
and of the SDF-1−CXCR7− group was 10 months. The
Table 1 Correlation between SDF-1 and CXCR7 expression and clinicopathological characteristics in pancreatic
adenocarcinoma
Clinicopathological characteristics SDF-1 (cases) CXCR7 (cases)
Positive Negative P Positive Negative P
Sex:
Male 18 26 >0.05 25 19 >0.05
Female 11 9 8 12
Age:
≤58 18 17 >0.05 20 15 >0.05
>58 11 18 13 16
Tumor size:
≤2 cm 3 10 >0.05 5 8 >0.05
>2 cm 26 25 8 23
Histological grade:
High 3 11 <0.05 8 6 >0.05
Moderate or low 26 24 25 25
TNM stage:
I or II 26 31 >0.05 30 27 >0.05
III or IV 3 4 3 4
Lymph node metastasis:
Positive 17 20 >0.05 25 12 <0.05
Negative 12 15 8 19
Distant metastasis:
Positive 3 3 >0.05 3 3 >0.05
Negative 26 32 30 28
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nificantly shorter than that of the SDF-1+CXCR7−/SDF-
1−CXCR7+ group and the SDF-1−CXCR7− group (P <0.05)
(Figure 3).
Discussion
Chemokines are a family of small cytokines with chemo-
taxis. In the past, chemokines were considered impor-
tant regulators in the development, differentiation, and
anatomic location of leukocytes [12,13]. However, recentFigure 1 Immunochemical staining of SDF-1 and CXCR7 in normal pa
expression of CXCR7 (×400).studies have indicated that chemokines and their recep-
tors played a critical role in the generation and develop-
ment in many types of malignant tumor, and that this role
was bidirectional [14,15]. Stromal cell-derived factor 1 is a
chemokine that is expressed in some cancer cells and is
involved in tumor cell migration and metastasis [16,17].
For many years, it was believed that CXCR4 was the
only receptor for SDF-1. However, several recent reports
have provided evidence that CXCR7 is another recep-
tor of SDF-1. As with SDF-1/CXCR4, the SDF-1/CXCR7ncreatic tissue. (A) Negative expression of SDF-1 (×400). (B) Negative
Figure 2 Immunochemical staining of SDF-1 and CXCR7 expression in pancreatic adenocarcinoma tissue. (A) Strong membranous and
cytoplasmic staining for SDF-1 (×400). (B) Strong membranous and cytoplasmic staining for CXCR7 (×400).
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genesis and the development and metastasis of tu-
mors [11,18,19].
CXCR7 is present on the surface of many different
malignant cell types [10], and on tumor-associated blood
vessels, but not on normal vasculature [7]; it promotes
the survival of tumor cells by preventing apoptosis, and
increasing adhesion properties and dissemination, but
does not mediate chemotaxis towards SDF-1 [10].
CXCR7 has been shown to induce proliferation of lung,
prostatic, and breast cancer cell lines, and supported
tumor growth enhancement and dissemination in a
breast cancer xenograft mouse model [7,10,11]. CXCR7
is poorly expressed in normal somatic cells. The litera-
ture suggests that CXCR7 is highly expressed in glioma,
colon cancer, lung cancer, breast cancer, prostatic cancer,
and tumor-associated vessels. However, neoplastically
non-transformed tissues express little CXCR7 protein;
CXCR7 is only detectable at the mRNA level by NorthernFigure 3 Kaplan-Meier curves for survival in patients with pancreaticblotting [7,20,21]. In our study, SDF-1 and CXCR7 was
expressed in the ductal cells of pancreatic adenocarcinoma
tissue; the expression rates of SDF-1 and CXCR7 were
45.3% and 51.6%, but the expressions of SDF-1 and
CXCR7 were negative in normal pancreatic tissues. The
expression difference between cancer tissues and normal
tissues was significant (P <0.05). This result suggests that
the SDF-1/CXCR7 biological axis might play a role in pan-
creatic tumorigenesis.
We also analyzed the relationship between SDF-1/
CXCR7 and the pancreatic adenocarcinoma biocharac-
ter. The expression of SDF-1 correlated with histological
grades; the expression rate in moderate to low differenti-
ation was higher than in high differentiation (P <0.05).
The expression of CXCR7 positively correlated with
lymph node metastasis (P <0.05). These results suggest
that expression of SDF-1 and CXCR7 might be involved
in invasion and metastasis of pancreatic cancer cells. Ex-
pression of SDF-1 was high in the lymph nodes and liveradenocarcinoma.
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creatic adenocarcinoma metastasis, so pancreatic cancer
cells expressing CXCR7 might migrate to corresponding
tissue through the expression gradient of SDF-1.
Degree of differentiation and lymph node metastasis
were prognostic factors of pancreatic adenocarcinoma;
low differentiation and lymph node metastasis indicated
poor prognosis [23,24]. Our research showed that the ex-
pression of SDF-1 and CXCR7 was related to histological
grades and lymph node metastasis of pancreatic adeno-
carcinoma, which means that their expression might
affect the survival of pancreatic adenocarcinoma patients.
Through statistical analysis, a single analysis shows that
there is no relation between expression of SDF-1 and
CXCR7 and prognosis. Combining analysis of the relation-
ship between expression of SDF-1 and CXCR7 and
prognosis revealed that the median survival time of
the SDF-1+CXCR7+ group was 6 months, of the SDF-
1+CXCR7−/SDF-1−CXCR7+ group was 9 months, and
of the SDF-1−CXCR7− group was 10 months. The survival
time of SDF-1+CXCR7+ group is significantly shorter
than the SDF-1+CXCR7−/SDF-1−CXCR7+ group and the
SDF-1−CXCR7− group (P <0.05).
Conclusions
Our data demonstrate that the SDF-1/CXCR7 biological
axis might be involved in the invasion and metastasis
of pancreatic adenocarcinoma. Both SDF-1 and CXCR7
might be useful markers for judging prognosis of pancre-
atic adenocarcinoma. Therefore, blocking this chemokine
receptor’s pathway with a chemokine receptor antagonist
or inhibitor might prove to be useful in a new strategy to
prevent pancreatic adenocarcinoma development.
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